Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Outlook Therapeutics (OTLK) EBITDA Margin (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed EBITDA Margin for 7 consecutive years, with 403.18% as the latest value for Q2 2025.

  • On a quarterly basis, EBITDA Margin changed N/A to 403.18% in Q2 2025 year-over-year; TTM through Dec 2025 was 3884.52%, a 667218.0% decrease, with the full-year FY2025 number at 4744.25%, down 701552.0% from a year prior.
  • EBITDA Margin was 403.18% for Q2 2025 at Outlook Therapeutics, down from 2677.76% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 403.18% in Q2 2025 to a low of 403.18% in Q2 2025.